Core Insights - He Yuan Bio (688238.SH) released its Q3 2025 financial report on October 28, 2025, indicating a total of 73.72 million shares held by five institutional investors, accounting for 11.36% of the company's total share capital [1] - The institutional holding percentage decreased by 1.53 percentage points compared to the previous quarter [1] Institutional Investors - The five institutional investors include Shanghai Zhangjiang Technology Venture Capital Co., Ltd., Zhejiang Huarui Shengyin Venture Capital Co., Ltd., Shanghai Tanying Investment Partnership (Limited Partnership), Shanghai Zhangjiang Torch Venture Capital Co., Ltd., and Shanghai Ouli Investment Management Center (Limited Partnership) [1] - The total institutional holding percentage stands at 11.36% [1] Public Funds - In this period, 67 public funds were not disclosed compared to the previous quarter, including notable funds such as Huatai-PB CSI Precision Medical Index (LOF) A, SSE Composite Index ETF, Guotai SSE Comprehensive ETF, and others [1]

Core Insights - Mike Biotech (300463.SZ) released its Q3 2025 report on October 25, 2025, indicating a total of 29.2165 million A-shares held by four institutional investors, accounting for 4.83% of the total share capital [1] - The institutional holding ratio decreased by 0.39 percentage points compared to the previous quarter [1] Institutional Investors - The institutional investors include: - China Merchants Securities Asset Management - Sun Li - China Merchants Asset Management Zhenxiang Value 2025001 Single Asset Management Plan - CITIC Securities Asset Management (Hong Kong) Limited - Client Funds - Hong Kong Central Clearing Limited [1] - The total institutional holding ratio is now 4.83% [1] Public Funds - A total of 97 public funds were not disclosed in this period compared to the previous quarter, including: - Southern CSI 1000 ETF - Huaxia CSI 1000 ETF - GF CSI 1000 ETF - Huitianfu Precision Medical Index (LOF) A - Medical Device ETF [1] Foreign Investment - One foreign fund, Hong Kong Central Clearing Limited, reduced its holdings by 0.12% compared to the previous quarter [1] - A new foreign institution disclosed this quarter is CITIC Securities Asset Management (Hong Kong) Limited - Client Funds [1]

Group 1 - The core point of the news is that Elysium Pharmaceuticals experienced a decline in stock price, dropping by 5.05% to 104.67 CNY per share, with a trading volume of 284 million CNY and a turnover rate of 0.59%, resulting in a total market capitalization of 47.101 billion CNY [1] - Elysium Pharmaceuticals, established on March 22, 2004, and listed on December 2, 2020, focuses on the research, production, and sales of innovative drugs, with 99.93% of its revenue coming from drug sales [1] Group 2 - From the perspective of major fund holdings, Elysium is heavily weighted in the Huatai-PineBridge fund, which reduced its holdings by 135,900 shares in the second quarter, now holding 587,300 shares, accounting for 4.73% of the fund's net value, making it the fifth-largest holding [2] - The Huatai-PineBridge fund, established on January 21, 2016, has a current scale of 778 million CNY, with a year-to-date return of 47.65% and a one-year return of 34.99% [2]

Group 1 - Berry Genomics (000710.SZ) released its 2024 annual report on April 25, 2025, indicating that as of April 24, 2025, 44 institutional investors disclosed holding A-shares, totaling 79.7934 million shares, which accounts for 22.57% of the total share capital [1] - The top ten institutional investors include Chengdu Tianxing Instrument (Group) Co., Ltd., Hongling Siqi (Zhuhai) M&A Equity Investment Enterprise (Limited Partnership), and others, with a combined holding ratio of 22.43%, reflecting a decrease of 1.55 percentage points compared to the previous quarter [1] - In the public fund sector, 37 new public funds were disclosed this period compared to the previous quarter, including funds such as Huatai-PB CSI Precision Medicine Index (LOF) A and Medical Device ETF [1] Group 2 - Foreign institutional investors that did not disclose holdings this period include MORGAN STANLEY & CO. INTERNATIONAL PLC, BARCLAYS BANK PLC, and J.P. Morgan Securities PLC - proprietary funds [2]